Evaluation of ivermectin antiviral activity against avian infectious bronchitis virus using a chicken embryo model

Int J Vet Sci Med. 2022 Mar 25;10(1):19-24. doi: 10.1080/23144599.2022.2050077. eCollection 2022.

Abstract

Ivermectin is widely used in both animals and humans as an FDA-approved parasiticide. Ivermectin has also been reported to have antiviral activity against several viruses including coronaviruses. There are reports that indicate ivermectin may have some role in diminishing the disease caused by SARS-CoV-2, but the evidence is inconclusive. The objective of this study was to determine if ivermectin was efficacious in inhibiting avian infectious bronchitis virus (IBV, a coronavirus) replication in chicken embryos. Briefly, our approach was to use the Massachusetts vaccine strain of IBV in combination with various doses of ivermectin and then inoculate these preparations into chicken embryos to determine if IBV replication was inhibited. The embryos were examined for IBV lesions and samples of chorioallantoic fluid were collected for IBV RT-PCR analysis. Several trials were performed, and the results of our study indicate that ivermectin did not inhibit IBV replication in chicken embryos.

Keywords: Ivermectin; antiviral; coronavirus; infectious bronchitis virus.

Grants and funding

This work was supported by the Agricultural Research Service [NC1180].